Lataa...
Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
PURPOSE: An oxaliplatin-based regimen is the most common adjuvant chemotherapy for patients with stage II/III colorectal cancer, but many patients experience dose reduction or early termination of chemotherapy due to side effects. We conducted this study to verify the range of reduction with oncolog...
Tallennettuna:
| Julkaisussa: | Ann Surg Treat Res |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Korean Surgical Society
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5880977/ https://ncbi.nlm.nih.gov/pubmed/29629354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4174/astr.2018.94.4.196 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|